Related Experiment Videos
Low dose interferon gamma for refractory Crohn's disease
H Debinski1, A Forbes, M A Kamm
1St. Mark's Hospital, London, England.
Italian Journal of Gastroenterology and Hepatology
|March 12, 1998
Summary
Interferon gamma shows potential for treating inflammatory bowel disease. In a pilot study, three of four patients with Crohn
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) management remains challenging, particularly for patients unresponsive to standard therapies.
- Cytokine modulation represents a potential therapeutic strategy for IBD.
Purpose of the Study:
- To evaluate the efficacy and safety of subcutaneous interferon gamma in patients with active Crohn's disease.
- To explore the potential role of interferon gamma in treating refractory IBD.
Main Methods:
- An open-label pilot study involving four patients with active Crohn's disease.
- Patients received subcutaneous interferon gamma (1.5 microgram/kg) three times weekly.
- Treatment was administered to patients unresponsive to standard immunosuppressive drugs.
Main Results:
- One patient achieved normal C-reactive protein and Crohn's disease activity index, becoming asymptomatic.
- Three out of four patients experienced a substantial fall in Crohn's disease activity index and normalized C-reactive protein.
- Treatment completion was affected by drug failure, side effects, and incidental disease in three patients.
Conclusions:
- Interferon gamma may offer a treatment option for patients with resistant Crohn's disease.
- Optimizing dosage and managing drug side effects are crucial for successful interferon gamma therapy in IBD.